Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Test-Retest Variability and Reliability of Volitional and Nonvolitional Assessments of Muscle Endurance in Healthy Humans.

Medicine and science in sports and exercise·2025

Same author

Minimizing the Risk of Surgical Site Infection Following Hip Fracture Operation.

Surgical infections·2024

Same author

[Blood gas analysis in the intensive cardiac care unit].

Giornale italiano di cardiologia (2006)·2024

Same author

Exploring the Perioperative Use of DOACs, off the Beaten Track.

Journal of clinical medicine·2024

Same author

Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) scientific statement on the simplification of the drug regimen for secondary cardiovascular prevention.

European heart journal supplements : journal of the European Society of Cardiology·2024

Same author

Italian Association of Hospital Cardiologists Position Paper 'Gender discrepancy: time to implement gender-based clinical management'.

European heart journal supplements : journal of the European Society of Cardiology·2024

Search research articles

Related Experiment Video

Updated: May 31, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins for acute coronary syndrome.

Noah Vale¹, Alain J Nordmann, Gregory G Schwartz

¹Family Medicine, St Mary's Hospital, McGill University, 377 Rue Jean Brilliant, Montreal, Quebec, Canada, H3T 1M5.

The Cochrane Database of Systematic Reviews

|June 17, 2011

Summary

Early statin therapy after acute coronary syndromes (ACS) did not reduce death or heart attack within four months. However, it significantly lowered unstable angina occurrences, with some risk of muscle toxicity, particularly with high-dose simvastatin.

More Related Videos

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

Related Experiment Videos

Last Updated: May 31, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

Area of Science:

Cardiology
Pharmacology
Clinical Trials

Background:

Acute coronary syndromes (ACS) pose a high risk for recurrent events and mortality.
The short-term impact of early statin treatment in ACS patients remains unclear.

Purpose of the Study:

To evaluate the benefits and harms of early statin administration in ACS patients.
Analysis based on randomized controlled trials (RCTs).

Main Methods:

Searched CENTRAL, MEDLINE, EMBASE, CINAHL up to February 2010.
Included RCTs comparing statins vs. placebo/usual care initiated within 14 days of ACS, with ≥30 days follow-up.
Pooled data using random effects models to calculate risk ratios (RRs).

Main Results:

18 RCTs (14,303 patients) analyzed.
No significant reduction in death, non-fatal myocardial infarction (MI), or stroke at 1 or 4 months.
Significant reduction in unstable angina at 4 months (RR 0.76).
Nine cases of myopathy (0.13%) with statins vs. one (0.015%) in controls; serious toxicity linked to simvastatin 80 mg.

Conclusions:

Early statin initiation within 14 days of ACS does not reduce mortality, MI, or stroke up to 4 months.
Early statin therapy effectively reduces unstable angina occurrence at 4 months post-ACS.
Potential for myopathy exists, especially with high-dose simvastatin.